FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1990485663> ?p ?o ?g. }

• W1990485663 endingPage "332" @default.
• W1990485663 startingPage "327" @default.
• W1990485663 abstract "Purpose To assess the long-term outcomes of intravitreal bevacizumab (IVB) in the treatment of choroidal neovascularization (CNV) secondary to presumed ocular histoplasmosis syndrome (POHS). Design Retrospective, comparative case series. Participants Interventional series of 150 eyes in 140 patients treated for subfoveal or juxtafoveal CNV secondary to POHS from January 2006 to January 2010. Intervention Intravitreal bevacizumab monotherapy or combination IVB and verteporfin photodynamic therapy (IVB/PDT). Main Outcome Measures Visual acuity (VA) at 12 and 24 months was analyzed. Secondary outcome measures included the number of injections per year and treatment-free intervals. Results A total of 117 eyes received IVB monotherapy, and 34 eyes underwent combination IVB/PDT treatment. For all patients, the average pretreatment logarithm of minimum angle of resolution (logMAR) was 0.63 (Snellen equivalent 20/86) with a 12-month logMAR VA of 0.45 (Snellen equivalent 20/56) and a 24-month logMAR VA of 0.44 (Snellen equivalent 20/55). The mean follow-up was 21.1 months with an average of 4.24 IVB injections per year. There was no significant difference in initial VA, VA at 12 months, VA at 24 months, or number of eyes with a 3-line gain between the IVB monotherapy and IVB/PDT groups. Thirty-eight percent (39/104) of eyes gained 3 lines or more, and 81.2% (84/104) of subjects had maintained or improved their starting VA at 1 year. The proportion of subjects maintaining a 3-line gain in VA was relatively preserved at 2 years (29.8%, 17/57) and 3 years (30.3%, 10/32) follow-up. There was no increase in the proportion of subjects losing 3 lines or more over 3 years of follow-up. Conclusions There is no significant difference in VA outcomes between IVB monotherapy versus IVB/PDT combination therapy. The use of IVB alone or in combination with PDT results in significant visual stabilization in the majority of patients with CNV secondary to POHS. Financial Disclosure(s) Proprietary or commercial disclosure may be found after the references. To assess the long-term outcomes of intravitreal bevacizumab (IVB) in the treatment of choroidal neovascularization (CNV) secondary to presumed ocular histoplasmosis syndrome (POHS). Retrospective, comparative case series. Interventional series of 150 eyes in 140 patients treated for subfoveal or juxtafoveal CNV secondary to POHS from January 2006 to January 2010. Intravitreal bevacizumab monotherapy or combination IVB and verteporfin photodynamic therapy (IVB/PDT). Visual acuity (VA) at 12 and 24 months was analyzed. Secondary outcome measures included the number of injections per year and treatment-free intervals. A total of 117 eyes received IVB monotherapy, and 34 eyes underwent combination IVB/PDT treatment. For all patients, the average pretreatment logarithm of minimum angle of resolution (logMAR) was 0.63 (Snellen equivalent 20/86) with a 12-month logMAR VA of 0.45 (Snellen equivalent 20/56) and a 24-month logMAR VA of 0.44 (Snellen equivalent 20/55). The mean follow-up was 21.1 months with an average of 4.24 IVB injections per year. There was no significant difference in initial VA, VA at 12 months, VA at 24 months, or number of eyes with a 3-line gain between the IVB monotherapy and IVB/PDT groups. Thirty-eight percent (39/104) of eyes gained 3 lines or more, and 81.2% (84/104) of subjects had maintained or improved their starting VA at 1 year. The proportion of subjects maintaining a 3-line gain in VA was relatively preserved at 2 years (29.8%, 17/57) and 3 years (30.3%, 10/32) follow-up. There was no increase in the proportion of subjects losing 3 lines or more over 3 years of follow-up. There is no significant difference in VA outcomes between IVB monotherapy versus IVB/PDT combination therapy. The use of IVB alone or in combination with PDT results in significant visual stabilization in the majority of patients with CNV secondary to POHS." @default.
• W1990485663 created "2016-06-24" @default.
• W1990485663 creator A5000814874 @default.
• W1990485663 creator A5009974614 @default.
• W1990485663 creator A5016039997 @default.
• W1990485663 creator A5030926281 @default.
• W1990485663 creator A5047679308 @default.
• W1990485663 creator A5059800807 @default.
• W1990485663 creator A5077396290 @default.
• W1990485663 creator A5086581165 @default.
• W1990485663 date "2012-02-01" @default.
• W1990485663 modified "2023-09-23" @default.
• W1990485663 title "Analysis of Outcomes for Intravitreal Bevacizumab in the Treatment of Choroidal Neovascularization Secondary to Ocular Histoplasmosis" @default.
• W1990485663 cites W110906275 @default.
• W1990485663 cites W1965141187 @default.
• W1990485663 cites W1975612140 @default.
• W1990485663 cites W1976851897 @default.
• W1990485663 cites W1984968613 @default.
• W1990485663 cites W1991963023 @default.
• W1990485663 cites W2004591462 @default.
• W1990485663 cites W2008833866 @default.
• W1990485663 cites W2011678962 @default.
• W1990485663 cites W2017593303 @default.
• W1990485663 cites W2019156888 @default.
• W1990485663 cites W2023516579 @default.
• W1990485663 cites W2034168366 @default.
• W1990485663 cites W2044475540 @default.
• W1990485663 cites W2049952535 @default.
• W1990485663 cites W2058725008 @default.
• W1990485663 cites W2062031871 @default.
• W1990485663 cites W2067780296 @default.
• W1990485663 cites W2075984382 @default.
• W1990485663 cites W2079361121 @default.
• W1990485663 cites W2079652281 @default.
• W1990485663 cites W2101898624 @default.
• W1990485663 cites W2142979206 @default.
• W1990485663 cites W2149380031 @default.
• W1990485663 cites W2152981071 @default.
• W1990485663 cites W4233505249 @default.
• W1990485663 cites W4249250897 @default.
• W1990485663 doi "https://doi.org/10.1016/j.ophtha.2011.08.032" @default.
• W1990485663 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22133795" @default.
• W1990485663 hasPublicationYear "2012" @default.
• W1990485663 type Work @default.
• W1990485663 sameAs 1990485663 @default.
• W1990485663 citedByCount "28" @default.
• W1990485663 countsByYear W19904856632012 @default.
• W1990485663 countsByYear W19904856632013 @default.
• W1990485663 countsByYear W19904856632014 @default.
• W1990485663 countsByYear W19904856632015 @default.
• W1990485663 countsByYear W19904856632016 @default.
• W1990485663 countsByYear W19904856632017 @default.
• W1990485663 countsByYear W19904856632018 @default.
• W1990485663 countsByYear W19904856632019 @default.
• W1990485663 countsByYear W19904856632020 @default.
• W1990485663 countsByYear W19904856632021 @default.
• W1990485663 countsByYear W19904856632022 @default.
• W1990485663 crossrefType "journal-article" @default.
• W1990485663 hasAuthorship W1990485663A5000814874 @default.
• W1990485663 hasAuthorship W1990485663A5009974614 @default.
• W1990485663 hasAuthorship W1990485663A5016039997 @default.
• W1990485663 hasAuthorship W1990485663A5030926281 @default.
• W1990485663 hasAuthorship W1990485663A5047679308 @default.
• W1990485663 hasAuthorship W1990485663A5059800807 @default.
• W1990485663 hasAuthorship W1990485663A5077396290 @default.
• W1990485663 hasAuthorship W1990485663A5086581165 @default.
• W1990485663 hasConcept C118487528 @default.
• W1990485663 hasConcept C141071460 @default.
• W1990485663 hasConcept C167135981 @default.
• W1990485663 hasConcept C2776694085 @default.
• W1990485663 hasConcept C2777802072 @default.
• W1990485663 hasConcept C2778257484 @default.
• W1990485663 hasConcept C2781148688 @default.
• W1990485663 hasConcept C2781359195 @default.
• W1990485663 hasConcept C71924100 @default.
• W1990485663 hasConceptScore W1990485663C118487528 @default.
• W1990485663 hasConceptScore W1990485663C141071460 @default.
• W1990485663 hasConceptScore W1990485663C167135981 @default.
• W1990485663 hasConceptScore W1990485663C2776694085 @default.
• W1990485663 hasConceptScore W1990485663C2777802072 @default.
• W1990485663 hasConceptScore W1990485663C2778257484 @default.
• W1990485663 hasConceptScore W1990485663C2781148688 @default.
• W1990485663 hasConceptScore W1990485663C2781359195 @default.
• W1990485663 hasConceptScore W1990485663C71924100 @default.
• W1990485663 hasIssue "2" @default.
• W1990485663 hasLocation W19904856631 @default.
• W1990485663 hasLocation W19904856632 @default.
• W1990485663 hasOpenAccess W1990485663 @default.
• W1990485663 hasPrimaryLocation W19904856631 @default.
• W1990485663 hasRelatedWork W1764554573 @default.
• W1990485663 hasRelatedWork W1993747607 @default.
• W1990485663 hasRelatedWork W2012546470 @default.
• W1990485663 hasRelatedWork W2023516579 @default.
• W1990485663 hasRelatedWork W2036634700 @default.
• W1990485663 hasRelatedWork W2065629733 @default.
• W1990485663 hasRelatedWork W2082077831 @default.
• W1990485663 hasRelatedWork W2412914714 @default.
• W1990485663 hasRelatedWork W2413182178 @default.

• next